Condition: Stargardt Disease · Sponsor: AAVantgarde Bio Srl
The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.
This description comes directly from the study's public registry record.
AAVantgarde Clinical Operations Lead · +448000465680 · clinicaltrials@aavantgarde.com
Always discuss trial participation with your own doctor first.
| Associated Retina Consultants | Phoenix, Arizona, United States | Recruiting |
| Retina Vitreous Associates Medical Group | Los Angeles, California, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Retina Consultants of Texas | Bellaire, Texas, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Moorfields Eye Hospital NHS Foundation Trust | London, England, United Kingdom | Recruiting |
| The Retina Clinic | London, England, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07161544